2007,Klox was founded.
Initial Launch Of Kleresca.
Received the 2019 Innovation Award at the Targeting Mitochondria Congress.
2007,
Klox was founded.
2011,
First FLE Biomodulation patent issued.
2013,
Received CE mark approval in Europe and Canadian approval for Kleresca.
2014,
Received CE mark approval in Europe for LumiHeal for the treatment of chronic and acute wounds.
2015,
Received CE mark approval in Europe for Perio-1, an adjunct treatment for periodontitis.
2016,
Initial launch of Kleresca.
2017,
Initial launch of LumiHeal.
2018,
Topline results presented at the European Wound Management Association (EWMA) for the treatment of chronic wounds. Plans to conduct U.S. 510(k) clinical trials for chronic wounds
2019,
Received the 2019 Innovation Award at the Targeting Mitochondria Congress.
2020,
KloxAsia headquarter was established in Hong Kong, the R & D center is in Guangzhou, China; LumiHeal and Kleresca have been classified as class III and Class II medical devices respectively, and will soon receive FDA approval.
2021,
Received NMPA approval in China for LumiHeal and Kleresca.
